DOM-METOPROLOL-L TABLET

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Aktivni sastojci:

METOPROLOL TARTRATE

Dostupno od:

DOMINION PHARMACAL

ATC koda:

C07AB02

INN (International ime):

METOPROLOL

Doziranje:

50MG

Farmaceutski oblik:

TABLET

Sastav:

METOPROLOL TARTRATE 50MG

Administracija rute:

ORAL

Jedinice u paketu:

300

Tip recepta:

Prescription

Područje terapije:

BETA-ADRENERGIC BLOCKING AGENTS

Proizvod sažetak:

Active ingredient group (AIG) number: 0111923002; AHFS:

Status autorizacije:

APPROVED

Datum autorizacije:

1997-04-24

Svojstava lijeka

PRODUCT MONOGRAPH
PR
DOM-METOPROLOL-L
Metoprolol Tartrate Tablets, USP
25 mg, 50 mg and 100 mg
Β-ADRENERGIC RECEPTOR BLOCKING AGENT
DOMINION PHARMACAL
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
DATE OF REVISION:
September 27, 2016
SUBMISSION CONTROL NO: 197897
_Dom-METOPROLOL-L Product Monograph _
_Page 2 of 38_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
..................................................................................
4
ADVERSE
REACTIONS..................................................................................................
10
DRUG INTERACTIONS
..................................................................................................
13
DOSAGE AND ADMINISTRATION
..............................................................................
17
OVERDOSAGE
................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 20
STORAGE AND STABILITY
..........................................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 24
PART II: SCIENTIFIC INFORMATION
...............................................................................
25
PHARMACEUTICAL
INFORMATION..........................................................................
25
DETAILED PHARMACOLOGY
.....................................................................................
26
TOXICOLOGY
.........................................